Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
June 11 2021 - 03:03AM
Immunicum Presents Data on Clinical Program DCP-001 at the European
Hematology Association (EHA) 2021 Virtual Congress
Immunicum Presents Data on Clinical
Program DCP-001 at the European Hematology Association (EHA) 2021
Virtual Congress
-- Ongoing ADVANCE II study evaluating DCP-001 in
AML patients is nearing target enrollment of 20 patients
--
Immunicum AB (publ; IMMU.ST) today
presents clinical data showing DCP-001’s ability to induce immune
responses to a broad range of tumor associated antigens in acute
myeloid leukemia (AML) patients, as well as preclinical results of
enhanced efficacy when combining DCP-001 with established AML
treatment regimens, at the EHA 2021 Virtual Congress, held from
June 9-17, 2021. The abstracts covering these presentations have
been communicated previously. The
E-posters can now be accessed through the conference platform and
at the Company’s corporate
website.
“The data presented at the EHA conference
underscores our confidence that DCP-001 can potentially improve the
poor treatment prognosis for AML patients by providing lasting
tumor control and prolonged clinical remission,” said
Jeroen Rovers, Chief Medical Officer at Immunicum.
“We are close to reaching the target enrollment in our ongoing
ADVANCE-II study evaluating DCP-001 in AML patients with measurable
residual disease, and look forward to be able to present more
results from this study at the end of this year. In addition, we
see based on preclinical data that DCP-001 has the potential to
improve treatment outcomes when combined with 5-AZA and venetoclax,
an established AML treatment regimen available to patients in the
US.”
ADVANCE II is an international, multi center,
open-label Phase II clinical study evaluating the efficacy and
safety of two different dosing regimens of Immunicum’s cancer
relapse vaccine candidate DCP-001 in patients with AML who are in
complete remission, but have persistent measurable residual disease
(MRD). Initial data on the study presented at the ASH 2020 Meeting,
demonstrated that treatment with DCP-001 is safe, well-tolerated
and with promising early signs of efficacy on converting patients
to an MRD negative status. The Company is on track to present
additional data on the study at the end of this year.
E-Posters presented at the EHA 2021 Virtual
Congress will be available for registered attendees through the
Virtual Congress platform starting Friday, June 11, 09:00 CEST as
well as on the Immunicum website.
For more information, please
contact:
Erik MantingChief Executive OfficerTelephone:
+31 713 322 627E-mail: ir@immunicum.com
INVESTOR RELATIONS
Sijme ZeilemakerHead of Investor Relations &
Corporate CommunicationTelephone: +46 8 732
8400E-mail: ir@immunicum.com
MEDIA RELATIONS:
Eva Mulder and Sophia HergenhanTrophic
CommunicationsTelephone: +49 175 222 57
56E-mail: immu@trophic.eu
About Immunicum AB
(publ)Immunicum is leveraging its unparalleled expertise
in dendritic cell biology to develop novel, off-the-shelf,
cell-based therapies for solid and blood-borne tumors. With
complementary therapeutic approaches in Phase II clinical
development that are based on intratumoral priming and cancer
relapse vaccination, the company aims to improve survival outcomes
and quality of life for a broad population of cancer patients.
Based in Sweden and the Netherlands, Immunicum is publicly traded
on the Nasdaq Stockholm. www.immunicum.com
- 20210611_ENG_Immunicum_EHA_Presentations_FINAL